3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Status
Completed
4
Recruiting
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Genitourinary
4
Conditions
Prostatic Neoplasms
4
Interventions
Docetaxel
158
Prednisone
131
Leuprolide
95
bicalutamide
86
enzalutamide
83
Radiotherapy
80
Goserelin
80
Abiraterone Acetate
76
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
54
Magnetic Resonance Spectroscopy
46
Zoledronic Acid
44
gallium 68 PSMA-11
37
Flutamide
34
abiraterone
32
Estramustine
32
radium Ra 223 dichloride
30
apalutamide
27
Surveys and Questionnaires
26
Gonadotropin-Releasing Hormone
26
Androgen Antagonists
25
cabazitaxel
24
Radiosurgery
24
Dutasteride
22
sipuleucel-T
21
Prednisolone
21
Triptorelin Pamoate
20
Paclitaxel
20
luprolide acetate gel depot
19
Radiation
19
Exercise
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Completed
×
Prostatic Neoplasms
×
fludrocortisone acetate
×
Clear all
NCT06104449
2026-04-27
MK-5684-005
Merck Sharp & Dohme LLC
Phase 1
Completed
7 enrolled
NCT06136598
2026-03-19
MK-5684-001
Merck Sharp & Dohme LLC
Phase 1
Completed
14 enrolled
NCT06566989
2024-10-23
MK-5684-008
Merck Sharp & Dohme LLC
Phase 1
Completed
8 enrolled
NCT06554639
2024-10-15
MK-5684-011
Merck Sharp & Dohme LLC
Phase 1
Completed
12 enrolled